webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Fmoc-L-Lys(N3-Gly)-OH

  CAS No.: 1198617-89-8   Cat No.: BADC-01687 4.5  

Fmoc-L-Lys(N3-Gly)-OH is a click chemistry reagent containing a lysine-containing azidoacetyl group building-block for SPPS.

Fmoc-L-Lys(N3-Gly)-OH

Structure of 1198617-89-8

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C23H25N5O5
Molecular Weight
451.48

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
(2S)-6-[(2-azidoacetyl)amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoic acid
Canonical SMILES
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)NC(CCCCNC(=O)CN=[N+]=[N-])C(=O)O
InChI
InChI=1S/C23H25N5O5/c24-28-26-13-21(29)25-12-6-5-11-20(22(30)31)27-23(32)33-14-19-17-9-3-1-7-15(17)16-8-2-4-10-18(16)19/h1-4,7-10,19-20H,5-6,11-14H2,(H,25,29)(H,27,32)(H,30,31)/t20-/m0/s1
InChIKey
IDSBAHSRCNJNIC-FQEVSTJZSA-N

Fmoc-L-Lys(N3-Gly)-OH is a modified amino acid derivative used in peptide synthesis, where it serves as a building block for the creation of peptides with specialized properties. The Fmoc (9-fluorenylmethyloxycarbonyl) group is a widely used protecting group for the amino terminus of peptides, allowing for stepwise peptide assembly through solid-phase peptide synthesis (SPPS). In this case, the Fmoc group enables selective deprotection and addition of subsequent amino acids, making Fmoc-L-Lys(N3-Gly)-OH a versatile intermediate in peptide synthesis.

The unique feature of Fmoc-L-Lys(N3-Gly)-OH is the inclusion of an azide (N3) group attached to the side chain of lysine, as well as a glycine (Gly) residue. The azide group enables the introduction of clickable chemistry, such as the copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction, also known as the "click" reaction. This click chemistry approach is used to covalently link peptides to other molecules, such as drugs, dyes, or biomolecules, in a highly selective and efficient manner. Fmoc-L-Lys(N3-Gly)-OH therefore plays a critical role in the creation of peptide conjugates for drug delivery, biomarker detection, and diagnostic applications.

Furthermore, the incorporation of the glycine residue (N3-Gly) enhances the flexibility of the peptide chain and can aid in achieving desired peptide conformations. This flexibility is beneficial in peptide-based applications that require structural adaptability, such as protein-protein interactions or the design of peptide scaffolds for molecular recognition. By using Fmoc-L-Lys(N3-Gly)-OH in synthesis, researchers can produce peptides that are tailored for specific structural and functional roles, including peptide libraries for high-throughput screening in drug discovery.

Another important application of Fmoc-L-Lys(N3-Gly)-OH is in the development of bioactive peptides for therapeutic purposes. The azide group enables the efficient conjugation of bioactive molecules to the peptide, enhancing its pharmacological properties or enabling targeted drug delivery. This compound is particularly valuable in the synthesis of targeted therapeutics, where peptides are conjugated with cytotoxic agents, fluorescent probes, or other biomolecules to improve specificity and efficacy in disease treatment. The ability to control the conjugation process with high precision makes Fmoc-L-Lys(N3-Gly)-OH an important tool in peptide-based drug design and delivery.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Tubulysin B | (2S,4R)-1-((S)-17-Amino-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide | 14-Hydroxy-3,6,9,12-tetraoxatetradecyl 4-methylbenzenesulfonate | 2,2,3,3-Tetramethyl-4,7,10,13-tetraoxa-3-silahexadecan-16-oic acid | Dov-Val-Dil-OtBu | 2,2-Dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl 4-methylbenzenesulfonate | N-Boc-Dap-Phe-OMe | Satralizumab Linker | 23-Hydroxy-3,6,9,12,15,18,21-heptaoxatricosyl 4-methylbenzenesulfonate | Fmoc-L-Lys(Pentynoyl-DIM)-OH | Fmoc-L-Lys(N3-Gly)-OH
Send Inquiry
Verification code
Inquiry Basket